Exploring the link between pholcodine exposure and neuromuscular blocking agent anaphylaxis

British Journal of Clinical Pharmacology

Volumn 78, Issue 1, 2014, Pages 14-23

  Brusch, Anna M ^a,b   Clarke, Russell C ^b   Platt, Peter R ^b   Phillips, Elizabeth J ^c,d  

^a FREMANTLE HOSPITAL   (Australia)

^b SIR CHARLES GAIRDNER HOSPITAL   (Australia)

^c MURDOCH UNIVERSITY   (Australia)

^d VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

anaphylaxis; drug hypersensitivity; neuromuscular blocking agent; pholcodine; substituted ammonium ions

Indexed keywords

AMMONIA; ATRACURIUM BESILATE; CETUXIMAB; IMMUNOGLOBULIN E; MORPHINE; NEUROMUSCULAR BLOCKING AGENT; PHOLCODINE; QUATERNARY AMMONIUM DERIVATIVE; ROCURONIUM; SUXAMETHONIUM; VECURONIUM; ALLERGEN; AMMONIUM DERIVATIVE; CODEINE; MORPHOLINE DERIVATIVE;

ALLERGENICITY; ANAPHYLAXIS; AUSTRALIA AND NEW ZEALAND; CROSS ALLERGY; CROSS REACTION; DISEASE ASSOCIATION; DRUG HYPERSENSITIVITY; DRUG RECALL; EUROPE; GEOGRAPHIC DISTRIBUTION; HUMAN; IMMEDIATE TYPE HYPERSENSITIVITY; INCIDENCE; NETHERLANDS; NORWAY; PATHOPHYSIOLOGY; PERIOPERATIVE PERIOD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SWEDEN; UNITED STATES; ANALOGS AND DERIVATIVES; CHEMICALLY INDUCED; IMMUNOLOGY; MEDICAL GEOGRAPHY;

ALLERGENS; AMMONIUM COMPOUNDS; ANAPHYLAXIS; CODEINE; CROSS REACTIONS; DRUG HYPERSENSITIVITY; GEOGRAPHY, MEDICAL; HUMANS; IMMUNOGLOBULIN E; MORPHOLINES; NEUROMUSCULAR BLOCKING AGENTS; NORWAY; PERIOPERATIVE PERIOD;

EID: 84902962572     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.12290     Document Type: Review

References (31)

1. Fisher MM, Baldo BA,. The incidence and clinical features of anaphylactic reactions during anesthesia in Australia. Ann Fr Anesth Reanim 1993; 12: 97-104.
2. Nel L, Eren E,. Peri-operative anaphylaxis. Br J Clin Pharmacol 2011; 71: 647-658.
3. Mertes PM, Alla F, Trechot P, Auroy Y, Jougla E,. Anaphylaxis during anesthesia in France: an 8-year national survey. J Allergy Clin Immunol 2011; 128: 366-373.
4. Harboe T, Guttormsen AB, Irgens A, Dybendal T, Florvaag E,. Anaphylaxis during anesthesia in Norway: a 6-year single-center follow-up study. Anesthesiology 2005; 102: 897-903.
5. Ebo DG, Fisher MM, Hagendorens MM, Bridts CH, Stevens WJ,. Anaphylaxis during anaesthesia: diagnostic approach. Allergy 2007; 62: 471-487.
6. Moneret-Vautrin DA, Gueant JL, Kamel L, Laxenaire MC, el Kholty S, Nicolas JP,. Anaphylaxis to muscle relaxants: cross-sensitivity studied by radioimmunoassays compared to intradermal tests in 34 cases. J Allergy Clin Immunol 1988; 82: (5 Pt 1): 745-752.
7. Sadleir PH, Clarke RC, Bunning DL, Platt PR,. Anaphylaxis to neuromuscular blocking drugs: incidence and cross-reactivity in Western Australia from 2002 to 2011. Br J Anaesth 2013; 110: 981-987.
8. Gurrieri C, Weingarten TN, Martin DP, Babovic N, Narr BJ, Sprung J, Volcheck GW,. Allergic reactions during anesthesia at a large United States referral center. Anesth Analg 2011; 113: 1202-1212.
9. Dong SW, Mertes PM, Petitpain N, Hasdenteufel F, Malinovsky JM,. Hypersensitivity reactions during anesthesia. Results from the ninth French survey (2005-2007). Minerva Anestesiol 2012; 78: 868-878.
10. Mertes PM, Laxenaire MC,. Adverse reactions to neuromuscular blocking agents. Curr Allergy Asthma Rep 2004; 4: 7-16.
11. Baldo BA, Fisher MM,. Substituted ammonium ions as allergenic determinants in drug allergy. Nature 1983; 306: 262-264.
12. Florvaag E, Johansson SG, Oman H, Venemalm L, Degerbeck F, Dybendal T, Lundberg M,. Prevalence of IgE antibodies to morphine. Relation to the high and low incidences of NMBA anaphylaxis in Norway and Sweden, respectively. Acta Anaesthesiol Scand 2005; 49: 437-444.
13. Florvaag E, Johansson SG, Oman H, Harboe T, Nopp A,. Pholcodine stimulates a dramatic increase of IgE in IgE-sensitized individuals. A pilot study. Allergy 2006; 61: 49-55.
14. Harboe T, Johansson SG, Florvaag E, Oman H,. Pholcodine exposure raises serum IgE in patients with previous anaphylaxis to neuromuscular blocking agents. Allergy 2007; 62: 1445-1450.
15. Florvaag E, Johansson SG, Irgens A, de Pater GH,. IgE-sensitization to the cough suppressant pholcodine and the effects of its withdrawal from the Norwegian market. Allergy 2011; 66: 955-960.
16. Johansson SG, Florvaag E, Oman H, Poulsen LK, Mertes PM, Harper NJ, Garvey LH, Gerth, van Wijk R, Metso T, Irgens A, Dybendal T, Halsey J, Seneviratne SL, Guttormsen AB,. National pholcodine consumption and prevalence of IgE-sensitization: a multicentre study. Allergy 2010; 65: 498-502.
17. International Narcotics Control Board. Estimated world requirements of narcotic drugs in gams for 2013. 2013. Available at http://www.incb.org/ documents/Narcotic-Drugs/Status-of-Estimates/2013/EstJan13.pdf (last accessed 7 April 2013).
18. Klinker JF, Seifert R,. Morphine and muscle relaxants are receptor-independent G-protein activators and cromolyn is an inhibitor of stimulated G-protein activity. Inflamm Res 1997; 46: 46-50.
19. Blunk JA, Schmelz M, Zeck S, Skov P, Likar R, Koppert W,. Opioid-induced mast cell activation and vascular responses is not mediated by mu-opioid receptors: an in vivo microdialysis study in human skin. Anesth Analg 2004; 98: 364-370, table of contents.
20. Barke KE, Hough LB,. Opiates, mast cells and histamine release. Life Sci 1993; 53: 1391-1399.
21. Reich A, Szepietowski JC,. Non-analgesic effects of opioids: peripheral opioid receptors as promising targets for future anti-pruritic therapies. Curr Pharm Des 2012; 18: 6021-6024.
22. Didier A, Cador D, Bongrand P, Furstoss R, Fourneron P, Senft M, Philip-Joet F, Charpin D, Charpin J, Vervloet D,. Role of the quaternary ammonium ion determinants in allergy to muscle relaxants. J Allergy Clin Immunol 1987; 79: 578-584.
23. Pichler WJ, Beeler A, Keller M, Lerch M, Posadas S, Schmid D, Spanou Z, Zawodniak A, Gerber B,. Pharmacological interaction of drugs with immune receptors: the p-i concept. Allergol Int 2006; 55: 17-25.
24. Baldo BA, Fisher MM, Pham NH,. On the origin and specificity of antibodies to neuromuscular blocking (muscle relaxant) drugs: an immunochemical perspective. Clin Exp Allergy 2009; 39: 325-344.
25. Chung CH, Mirakhur B, Chan E, Le QT, Berlin J, Morse M, Murphy BA, Satinover SM, Hosen J, Mauro D, Slebos RJ, Zhou Q, Gold D, Hatley T, Hicklin DJ, Platts-Mills TA,. Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose. N Engl J Med 2008; 358: 1109-1117.
26. Commins SP, James HR, Kelly LA, Pochan SL, Workman LJ, Perzanowski MS, Kocan KM, Fahy JV, Nganga LW, Ronmark E, Cooper PJ, Platts-Mills TA,. The relevance of tick bites to the production of IgE antibodies to the mammalian oligosaccharide galactose-alpha-1,3-galactose. J Allergy Clin Immunol 2011; 127: 1286-1293 e6.
27. Mullins RJ, James H, Platts-Mills TAE, Commins S,. Relationship between red meat allergy and sensitization to gelatin and galactose-alpha-1,3-galactose. J Allergy Clin Immunol 2012; 129: 1334-1342.e1 (Electronic).
28. Findlay JW,. Pholcodine. J Clin Pharm Ther 1988; 13: 5-17.
29. Guttormsen AB., Allergic reactions during anaesthesia-increased attention to the problem in Denmark and Norway. Acta Anaesthesiol Scand 2001; 45: 1189-1190.
30. Laake JH, Rottingen JA,. Rocuronium and anaphylaxis-a statistical challenge. Acta Anaesthesiol Scand 2001; 45: 1196-1203.
31. Florvaag E, Johansson SG, Irgens A, de Pater GH,. IgE-sensitization to the cough suppressant pholcodine and the effects of its withdrawal from the Norwegian market. Allergy 2011; 66: 955-960.